IL110471A - Oral preparations are soluble in water containing estron history - Google Patents

Oral preparations are soluble in water containing estron history

Info

Publication number: IL110471A
Authority: IL; Israel
Prior art keywords: calcium; compositions according; pharmaceutical compositions; oral; soluble
Prior art date: 1993-09-17

Application number

IL11047194A

Other languages

English (en)

Hebrew (he)

Other versions

IL110471A0 (en

Original Assignee

Deghenghi Romano

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-07-27

Publication date

1998-10-30

1994-07-27 Application filed by Deghenghi Romano filed Critical Deghenghi Romano

1994-10-21 Publication of IL110471A0 publication Critical patent/IL110471A0/xx

1998-10-30 Publication of IL110471A publication Critical patent/IL110471A/en

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
150000002167 estrones Chemical class 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 32
229940011871 estrogen Drugs 0.000 claims abstract description 20
239000000262 estrogen Substances 0.000 claims abstract description 20
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 claims abstract description 15
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 14
159000000007 calcium salts Chemical class 0.000 claims abstract description 14
229940081345 estropipate Drugs 0.000 claims abstract description 14
229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 6
229950008385 estrone sulphate Drugs 0.000 claims abstract description 5
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
229910000020 calcium bicarbonate Inorganic materials 0.000 claims abstract description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
239000007788 liquid Substances 0.000 claims description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
239000001736 Calcium glycerylphosphate Substances 0.000 claims description 7
235000010216 calcium carbonate Nutrition 0.000 claims description 7
UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 7
229940095618 calcium glycerophosphate Drugs 0.000 claims description 7
235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 7
108010011485 Aspartame Proteins 0.000 claims description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
229930006000 Sucrose Natural products 0.000 claims description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
239000000605 aspartame Substances 0.000 claims description 6
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
229960003438 aspartame Drugs 0.000 claims description 6
235000010357 aspartame Nutrition 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
229960004793 sucrose Drugs 0.000 claims description 6
239000003826 tablet Substances 0.000 claims description 6
239000008118 PEG 6000 Substances 0.000 claims description 5
229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
235000013681 dietary sucrose Nutrition 0.000 claims description 5
239000008187 granular material Substances 0.000 claims description 5
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims description 4
239000001530 fumaric acid Substances 0.000 claims description 4
235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
239000000796 flavoring agent Substances 0.000 claims description 3
235000019359 magnesium stearate Nutrition 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
235000012239 silicon dioxide Nutrition 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
XKZZNHPZEPVUQK-JEDNCBNOSA-N (2s)-2-amino-4-methylpentanoic acid;hydron;chloride Chemical compound Cl.CC(C)C[C@H](N)C(O)=O XKZZNHPZEPVUQK-JEDNCBNOSA-N 0.000 claims description 2
NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
239000012153 distilled water Substances 0.000 claims description 2
235000019634 flavors Nutrition 0.000 claims description 2
229940043202 calcium cyclamate Drugs 0.000 claims 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims 1
LFVPBERIVUNMGV-UHFFFAOYSA-N fasudil hydrochloride Chemical compound Cl.C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 LFVPBERIVUNMGV-UHFFFAOYSA-N 0.000 claims 1
-1 bicarbonate compound Chemical class 0.000 abstract description 5
150000001875 compounds Chemical class 0.000 abstract description 3
150000007524 organic acids Chemical class 0.000 abstract 2
238000002360 preparation method Methods 0.000 description 13
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical class OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 12
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 10
239000011575 calcium Substances 0.000 description 10
229960003399 estrone Drugs 0.000 description 10
229910052791 calcium Inorganic materials 0.000 description 9
239000004615 ingredient Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 5
239000002253 acid Substances 0.000 description 5
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000007938 effervescent tablet Substances 0.000 description 4
206010065687 Bone loss Diseases 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
206010039984 Senile osteoporosis Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
239000007935 oral tablet Substances 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229960005141 piperazine Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
102100021022 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
101100321409 Rattus norvegicus Zdhhc23 gene Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229940069978 calcium supplement Drugs 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940035811 conjugated estrogen Drugs 0.000 description 1
238000000151 deposition Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
229940021013 electrolyte solution Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
150000002159 estradiols Chemical class 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229960001893 piperazine sulfate Drugs 0.000 description 1
MYNIYCGOBKAQAO-UHFFFAOYSA-N piperazine;sulfuric acid Chemical compound OS(O)(=O)=O.C1CNCCN1 MYNIYCGOBKAQAO-UHFFFAOYSA-N 0.000 description 1
NDPBYMFTBWPSNB-UHFFFAOYSA-N piperazine;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1CNCCN1 NDPBYMFTBWPSNB-UHFFFAOYSA-N 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229960000747 sodium estrone sulfate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

IL11047194A 1993-09-17 1994-07-27 Oral preparations are soluble in water containing estron history IL110471A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITMI932014A IT1270831B (it)	1993-09-17	1993-09-17	Composizioni farmaceutiche orali effervescenti contenenti estrone

Publications (2)

Publication Number	Publication Date
IL110471A0 IL110471A0 (en)	1994-10-21
IL110471A true IL110471A (en)	1998-10-30

Family

ID=11366921

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11047194A IL110471A (en)	1993-09-17	1994-07-27	Oral preparations are soluble in water containing estron history

Country Status (12)

Country	Link
US (1)	US5720977A (de)
EP (1)	EP0719148B1 (de)
JP (1)	JPH09502709A (de)
KR (1)	KR100314338B1 (de)
AT (1)	ATE163265T1 (de)
AU (1)	AU7532994A (de)
CA (1)	CA2171829A1 (de)
DE (1)	DE69408579T2 (de)
ES (1)	ES2112555T3 (de)
IL (1)	IL110471A (de)
IT (1)	IT1270831B (de)
WO (1)	WO1995007701A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997004752A1 (en) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
US6726922B1 (en)	1999-06-28	2004-04-27	Minu, L.L.C.	Process and composition for temporarily suppressing pain
EP1210368A2 (de) *	1999-09-08	2002-06-05	Immunex Corporation	Verwendung von semaphorin zur modulierung des zellausflusses
PT1591121E (pt) *	2000-12-14	2009-07-20	Ortho Mcneil Janssen Pharm	Processo para preparar produtos de hormona esteróide compreendendo um agente estabilizante na forma não cristalina
US6630166B1 (en)	2001-02-12	2003-10-07	Watson Pharmaceuticals, Inc.	Compositions for conjugated estrogens and associated methods
US7303763B2 (en) *	2001-02-12	2007-12-04	Watson Laboratories, Inc.	Compositions for conjugated estrogens and associated methods
US20030068356A1 (en)	2001-07-10	2003-04-10	Pather S. Indiran	Sequential drug delivery systems
US20050089502A1 (en) *	2003-08-21	2005-04-28	Todd Schansberg	Effervescent delivery system
EP1853272A1 (de) *	2005-02-03	2007-11-14	Duramed Pharmaceuticals, Inc.	Zusammensetzungen aus unkonjugierten östrogenen und anwendungsverfahren dafür
WO2007076144A2 (en) *	2005-12-27	2007-07-05	Duramed Pharmaceuticals, Inc.	Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5004651A (en) *	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms

1993
- 1993-09-17 IT ITMI932014A patent/IT1270831B/it active IP Right Grant
1994
- 1994-07-26 WO PCT/EP1994/002465 patent/WO1995007701A1/en not_active Ceased
- 1994-07-26 AT AT94925394T patent/ATE163265T1/de not_active IP Right Cessation
- 1994-07-26 DE DE69408579T patent/DE69408579T2/de not_active Expired - Fee Related
- 1994-07-26 CA CA002171829A patent/CA2171829A1/en not_active Abandoned
- 1994-07-26 US US08/592,377 patent/US5720977A/en not_active Expired - Fee Related
- 1994-07-26 EP EP94925394A patent/EP0719148B1/de not_active Expired - Lifetime
- 1994-07-26 ES ES94925394T patent/ES2112555T3/es not_active Expired - Lifetime
- 1994-07-26 KR KR1019960701321A patent/KR100314338B1/ko not_active Expired - Fee Related
- 1994-07-26 JP JP7508930A patent/JPH09502709A/ja not_active Ceased
- 1994-07-26 AU AU75329/94A patent/AU7532994A/en not_active Abandoned
- 1994-07-27 IL IL11047194A patent/IL110471A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1995007701A1 (en)	1995-03-23
ES2112555T3 (es)	1998-04-01
JPH09502709A (ja)	1997-03-18
IL110471A0 (en)	1994-10-21
EP0719148A1 (de)	1996-07-03
ITMI932014A0 (it)	1993-09-17
EP0719148B1 (de)	1998-02-18
ATE163265T1 (de)	1998-03-15
US5720977A (en)	1998-02-24
CA2171829A1 (en)	1995-03-23
AU7532994A (en)	1995-04-03
DE69408579D1 (de)	1998-03-26
IT1270831B (it)	1997-05-13
KR100314338B1 (ko)	2002-02-28
ITMI932014A1 (it)	1995-03-17
DE69408579T2 (de)	1998-06-18

Legal Events

Date	Code	Title
1999-03-12	FF	Patent granted
1999-10-28	KB	Patent renewed
2000-12-06	KB	Patent renewed
2004-09-27	KB	Patent renewed
2009-09-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5073374A (en)	1991-12-17	Fast dissolving buccal tablet
US5112616A (en)	1992-05-12	Fast dissolving buccal tablet
CA1306686C (en)	1992-08-25	Pharmaceutical composition containing ibuprofen
JP4801255B2 (ja)	2011-10-26	沸騰性酸−塩基対を含有する製薬学的組成物
EP0524579B1 (de)	1998-03-11	Verbesserte und dosierte orale Formulierungen von Dideoxypurinenukleosiden
EP2029146B1 (de)	2017-12-20	Verfahren zur verabreichung fester dosierungsformen von ethinyl-estradiol und prodrugs davon mit verbesserter bioverfügbarkeit
JPS62149615A (ja)	1987-07-03	鎮痛作用を有する沸騰組成物
CZ156598A3 (cs)	1998-08-12	Použití flurbiprofenu k přípravě léčiva k léčení bolesti v krku
US5720977A (en)	1998-02-24	Oral water soluble pharmaceutical compositions containing estrone compound and calcium salt
US4190655A (en)	1980-02-26	Amiloride citrate
AU2013346766A1 (en)	2015-05-21	Effervescent tablet
EP1651191B1 (de)	2008-11-12	Sprudelnde pharmazeutische zusammensetzungen mit vitamin d, calcium und phospat und ihre therapeutische verwendung
US20080145454A1 (en)	2008-06-19	Compositions to alleviate herpes virus symptoms
JPH0656677A (ja)	1994-03-01	制酸剤組成物
GB2174004A (en)	1986-10-29	Effervescent tablets
RU2276982C2 (ru)	2006-05-27	Средство, обладающее противовоспалительным, анальгетическим, жаропонижающим действием в форме таблетки
US20260090985A1 (en)	2026-04-02	Oral mucosal formulations of aspirin
KR100631873B1 (ko)	2006-10-09	생체이용율이 증진된 알렌드론산 제제